Literature DB >> 8113153

The contractile mechanism of beraprost sodium, a stable prostacyclin analog, in the isolated canine femoral vein.

M Ishikawa1, A Namiki.   

Abstract

The vascular contractile mechanism of prostacyclin (PGI2) was investigated using beraprost sodium (BPS), a stable PGI2 analog. Ring strips without endothelium isolated from canine femoral veins and arteries were used. BPS induced a dose-dependent contraction without precontraction and after precontraction with norepinephrine (NE) or 60 mM K+ in the veins. In contrast, BPS induced a dose-dependent relaxation after precontraction with U46619, a thromboxane A2 (TXA2) analog, or prostaglandin F2 alpha (PGF2 alpha) in the veins. In the arteries, BPS induced contraction at higher concentrations after precontraction with NE. However, BPS relaxed arteries dose-dependently after precontraction with PGF2 alpha. By pretreatment with 13-azaprostanoic acid (13-APA), a TXA2/endoperoxide receptor antagonist, the dose-response curve of BPS in the veins was shifted to the right. Schild plot analysis resulted in a linear regression with a slope of 0.86 +/- 0.13, which was not significantly different from unity, and the pA2 value for 13-APA against BPS was 7.10 +/- 0.06. By pretreatment with BPS, the dose-response curve of U46619 in the veins was shifted to the right. Kaumann plot analysis resulted in a linear regression with a slope of 0.89 +/- 0.09, which was not significantly different from unity, and the pA2 value for BPS against U46619 was 5.68 +/- 0.04. These findings indicate that BPS is a partial agonist for the TXA2/endoperoxide receptors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8113153     DOI: 10.1007/bf01744491

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  21 in total

1.  Cloning and expression of cDNA for a human thromboxane A2 receptor.

Authors:  M Hirata; Y Hayashi; F Ushikubi; Y Yokota; R Kageyama; S Nakanishi; S Narumiya
Journal:  Nature       Date:  1991-02-14       Impact factor: 49.962

2.  The effects of prostacyclin (PGI2) on tissues which detect prostaglandins (PG'S).

Authors:  C Omini; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1977-10

3.  Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation.

Authors:  S Bunting; R Gryglewski; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1976-12

4.  Comparison of the actions of U-46619, a prostaglandin H2-analogue, with those of prostaglandin H2 and thromboxane A2 on some isolated smooth muscle preparations.

Authors:  R A Coleman; P P Humphrey; I Kennedy; G P Levy; P Lumley
Journal:  Br J Pharmacol       Date:  1981-07       Impact factor: 8.739

5.  The effect of prostacyclin on the human umbilical artery.

Authors:  K Pomerantz; A Sintetos; P Ramwell
Journal:  Prostaglandins       Date:  1978-06

6.  Some quantitative uses of drug antagonists.

Authors:  O ARUNLAKSHANA; H O SCHILD
Journal:  Br J Pharmacol Chemother       Date:  1959-03

7.  Characterization of a novel metabolic pathway of arachidonate in coronary arteries which generates a potent endogenous coronary vasodilator.

Authors:  A Raz; P C Isakson; M S Minkes; P Needleman
Journal:  J Biol Chem       Date:  1977-02-10       Impact factor: 5.157

8.  Contractile responses to prostacyclin (PGI2) of isolated human saphenous and rat venous tissue.

Authors:  J V Levy
Journal:  Prostaglandins       Date:  1978-07

9.  Prostacyclin (PGX) is the endogenous metabolite responsible for relaxation of coronary arteries induced by arachindonic acid.

Authors:  G J Dusting; S Moncada; J R Vane
Journal:  Prostaglandins       Date:  1977-01

10.  Prostacyclin potentiates 13-azaprostanoic acid-induced platelet deaggregation.

Authors:  L V Parise; D L Venton; G C Le Breton
Journal:  Thromb Res       Date:  1982-12-15       Impact factor: 3.944

View more
  2 in total

Review 1.  Beraprost: a review of its pharmacology and therapeutic efficacy in the treatment of peripheral arterial disease and pulmonary arterial hypertension.

Authors:  Ezequiel Balmori Melian; Karen L Goa
Journal:  Drugs       Date:  2002       Impact factor: 9.546

2.  Decreased contraction induced by endothelium-derived contracting factor in prolonged treatment of rat renal artery with endoplasmic reticulum stress inducer.

Authors:  Makoto Ando; Takayuki Matsumoto; Kumiko Taguchi; Tsuneo Kobayashi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2018-05-04       Impact factor: 3.000

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.